Research - UniQure went through some interesting de-risking two weeks back with the release of initial data (the first publicly) from Baxter International’s (BAX) Hemophilia B gene therapy program, … Continue Reading
Read nowInsights - Genzyme (of Sanofi [SNY]) announced on Wednesday a collaboration with the private gene therapy company Voyager Therapeutics.
Read nowResearch - We see uniQure (QURE) as a dark horse in gene therapy, in-part because of numerous catalysts in 2015 that will put fresh eyes on this European company.
Read now- Alnylam (NASDAQ: ALNY) reported positive Phase I proof-of-concept and safety results for ALN-TTR02, the company’s most advanced wholly-owned compound. ALN-TTR02 is being developed to treat Transthyretin-Mediated … Continue Reading
Read nowInsights - Affimed (AFMD) released Q2 2021 business update today and it was mixed. AFM13 + MD Anderson collaboration in blood cancers seems to be progressing well, with data … Continue Reading
PremiumInsights - Affimed had the Q1 business update call this morning. The call was not well received after the company did not shed much light on AFM24 progress and … Continue Reading
PremiumInsights - The winner of ASH 2020, the annual blood disease conference, is Fate Therapeutics (FATE). FATE stock is up >30% this morning to a $7B valuation … Continue Reading
Premium
